Furthermore, KLF6 downregulation was correlated with activated EGFR and phosphorylated AKT in patient-derived lung adenocarcinoma samples and decreased KLF6-induced resistance to erlotinib both in vitro and in vivo [55]. The gene discussed is EGFR; the disease is lung adenocarcinoma.